IntegraGen

Executive Summary

IntegraGen is a French genomics company that translates molecular research into clinical diagnostics, specializing in oncology and genetic diseases. Founded in 2000 and based in Evry, the company develops molecular tests and offers advanced sequencing services and bioinformatics tools. Its platform is used in renowned institutes, positioning it as a key player in precision medicine. IntegraGen's test portfolio includes non-invasive prenatal testing, hereditary cancer panels, and companion diagnostics, leveraging high-throughput sequencing to improve patient outcomes. The company operates in a growing market driven by increasing demand for genomic-based personalized medicine. While private and with limited public financial data, IntegraGen benefits from long-standing collaborations and a strong scientific foundation. Key challenges include competition from larger firms and regulatory hurdles in Europe. Potential growth drivers include expanding test menu, forging pharma partnerships, and penetrating global markets. With its established infrastructure and focus on innovation, IntegraGen is well-placed to capitalize on the genomics revolution.

Upcoming Catalysts (preview)

• H2 2026Launch of new hereditary cancer panel70% success
• Q4 2026Strategic partnership for AI-driven genomic analysis60% success
• Q1 2027CE marking for expanded non-invasive prenatal test50% success